Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia

The primary aim of this study is to assess the predictive value of six molecular markers in determining PRCa risk in patients with BPH. These molecular markers are: (A)- Two polymorphic repeats, (CAG)<sub>n</sub> and (GGN)<sub>n</sub>, in the androgen receptor (<i>AR<...

Full description

Bibliographic Details
Main Author: Tayeb, Mohammed Taher
Published: University of Aberdeen 2002
Subjects:
616
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248613
id ndltd-bl.uk-oai-ethos.bl.uk-248613
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-2486132017-04-20T03:31:24ZGenetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasiaTayeb, Mohammed Taher2002The primary aim of this study is to assess the predictive value of six molecular markers in determining PRCa risk in patients with BPH. These molecular markers are: (A)- Two polymorphic repeats, (CAG)<sub>n</sub> and (GGN)<sub>n</sub>, in the androgen receptor (<i>AR</i>) gene; (B)- A single nucleotide polymorphism (SNP) in the (-290 A to G) 5' regulatory region of the <i>CYP3A4 </i>gene; (C)- Two SNPs (<i>Taq</i>I and <i>Fok</i>I) in vitamin D receptor (<i>VDR</i>) gene; (D)- A SNP (Val655Ile) in the transmembrane domain coding region of <i>HER2</i> gene. The study evaluated 28 patients who presented with PRCa at least 3 years and up to 15 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The results of this study showed that <i>CYP3A4</i> variant genotype identified men with BPH who are at increased risk of developing PRCa (odds ratio 5.2, 95% CI = 1.8-14.3). Similar finding was also seen for <i>VDR Taq</i>I SNP, where TT genotype was associated with a significant 5 fold increase in the risk of developing PRCa in patients previously diagnosed with BPH. Tentative evidence of association between risk of developing PRCa and the variant genotype of <i>HER2 </i>and <i>VDR Fok</i>I SNPs was also demonstrated, although the results were not statistically significant. The odds ratio of developing PRCa was 1.88, and 2.33 in BPH patients having <i>HER</i>2 Ile/Ile genotype and <i>VDR Fok</i>I FF genotype respectively. This study also showed no evidence for association between the size of <i>AR </i>CAG and GGN repeats and the risk of the development of PRCa in patients with BPH. However, data of this study suggest that BPH patients with <i>AR </i>CAG instability have a 12 fold increase risk in development PRCa. These results provide a potential tool to assist prediction strategies for this important disease.616ProstateUniversity of Aberdeenhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248613http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU154536Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616
Prostate
spellingShingle 616
Prostate
Tayeb, Mohammed Taher
Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
description The primary aim of this study is to assess the predictive value of six molecular markers in determining PRCa risk in patients with BPH. These molecular markers are: (A)- Two polymorphic repeats, (CAG)<sub>n</sub> and (GGN)<sub>n</sub>, in the androgen receptor (<i>AR</i>) gene; (B)- A single nucleotide polymorphism (SNP) in the (-290 A to G) 5' regulatory region of the <i>CYP3A4 </i>gene; (C)- Two SNPs (<i>Taq</i>I and <i>Fok</i>I) in vitamin D receptor (<i>VDR</i>) gene; (D)- A SNP (Val655Ile) in the transmembrane domain coding region of <i>HER2</i> gene. The study evaluated 28 patients who presented with PRCa at least 3 years and up to 15 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The results of this study showed that <i>CYP3A4</i> variant genotype identified men with BPH who are at increased risk of developing PRCa (odds ratio 5.2, 95% CI = 1.8-14.3). Similar finding was also seen for <i>VDR Taq</i>I SNP, where TT genotype was associated with a significant 5 fold increase in the risk of developing PRCa in patients previously diagnosed with BPH. Tentative evidence of association between risk of developing PRCa and the variant genotype of <i>HER2 </i>and <i>VDR Fok</i>I SNPs was also demonstrated, although the results were not statistically significant. The odds ratio of developing PRCa was 1.88, and 2.33 in BPH patients having <i>HER</i>2 Ile/Ile genotype and <i>VDR Fok</i>I FF genotype respectively. This study also showed no evidence for association between the size of <i>AR </i>CAG and GGN repeats and the risk of the development of PRCa in patients with BPH. However, data of this study suggest that BPH patients with <i>AR </i>CAG instability have a 12 fold increase risk in development PRCa. These results provide a potential tool to assist prediction strategies for this important disease.
author Tayeb, Mohammed Taher
author_facet Tayeb, Mohammed Taher
author_sort Tayeb, Mohammed Taher
title Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
title_short Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
title_full Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
title_fullStr Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
title_full_unstemmed Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
title_sort genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia
publisher University of Aberdeen
publishDate 2002
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248613
work_keys_str_mv AT tayebmohammedtaher geneticriskfactorsinfluencingthedevelopmentofprostatecancerinpatientswithbenignprostatichyperplasia
_version_ 1718441368786829312